The shadow of generic competition has repeatedly loomed over copyright’s blockbuster drug, Sildenafil, triggering questions about the prospects of related medicinal portfolios. While initial periods saw substantial gains, the intellectual property lapse has created the door for cheaper copies, likely reducing profitability and creating a genuine